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Abstract
Background: The aim of the present study was to investigate the seroprevalence and
sociodemographic data, health-related and occupational factors and other correlates of sero-
posivity among dentists in the city of Belo Horizonte, MG, Brazil.
Methods: A cross-sectional survey was carried out with 1302 dentists in Belo Horizonte, Brazil.
All dentists were tested for anti-HCV using a commercially available enzyme-linked
immunosorbent assay (ELISA). Individuals positive for anti-HCV were recalled for further
evaluation. The presence of HCV RNA in anti-HCV-positive samples was assessed using reverse
transcription-polymerase chain reaction (RT-PCR). Data on demographic, behavioural and
occupational exposure aspects were collected through questionnaires.
Results: The seroprevalence of anti-HCV was 0.9% (95% IC 0.5-1.7%). The factors associated to
the prevalence of hepatitis C were history of blood transfusion (p = 0.002) and having undergone
a test for hepatitis C (p = 0.015).
Conclusions: The seroprevalence of anti-HCV among dentists is low. Moreover, no occupational
exposure was associated to the seroprevalence of hepatitis C.
Background
Healthcare-associated infection is an important public
health problem worldwide, with ever-increasing interest
on the part of politicians, patients and healthcare workers
[1,2]. Healthcare providers are at risk of infection from
blood-borne pathogens, including hepatitis B (HBV),
human deficiency (HIV) and hepatitis C virus (HCV) [3-
6]. The transmission of blood-borne viruses in dental
offices is a potential hazard to patients and dental staff,
particularly to oral and maxillofacial surgeons [7,8].
Chronic hepatitis C is the leading cause of chronic liver
disease, cirrhosis, hepatocellular carcinoma (HCC) and
liver transplants in Europe and the United States [9-11].
As HCV is transmitted primarily by contaminated blood,
it represents a higher risk of nosocomial transmission to
patients and healthcare workers [10-12].
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infected patients and is not identified unless specific diag-
nostic tests are performed. Most infected individuals are
diagnosed at a later date or when abnormal blood or liver
function tests are found in routine examinations for other
reasons [12,13].
The current antiviral treatment for chronic HCV infection
(pegylated interferon plus ribavirin) provides virus clear-
ance in about 55% of patients with genotype 1 and in
80% of those with genotypes 2 or 3 [14-17]. Hence, the
diagnosis of patients infected with chronic HCV is manda-
tory, since the antiviral treatment might halt or slow the
progression of hepatitis to cirrhosis or the development of
HCC [13-18].
According to the World Health Organization (WHO) [9],
serological HCV tests are strongly recommended for intra-
venous drug users, people who received plasma-derived
products or solid organ transplants before 1992, patients
with kidney failure patients on dialysis and children born
from women positive for HCV women [19,20] as well as
part of the investigation of any liver disease [19,21].
HCV testing is also routinely recommended for healthcare
professionals, especially for medical and nursing staffs,
following needle stick injuries or mucosal exposure to
HCV-positive blood. Dentists appear particularly prone to
blood-borne infections, as their routine practice includes
the use of sharp instruments in an environment contami-
nated with saliva and blood. Although virus transmission
via saliva may be possible, the major occupational risk is
accidental needle stick injuries [22].
Few reports on the prevalence of HCV prevalence in Brazil
have been published, with findings ranging from 1.42%
in the general population of the city of São Paulo [23] to
1.7% in an Amerindian population in the Brazilian Ama-
zon region [24]. Other studies have been carried out
involving specific groups, such as blood donors (0.9%)
[25], intravenous drug users (69.0%) [26], dialysis
patients (23.8%-52.0%) [27-29], HIV patients (17.7%)
[30], prisoners (16.0%) [31] and ex-soccer players
(7.5%), who are considered to be at high risk of HCV
infection associated with the intravenous injections of
vitamins and the use of stimulants before games [32]. As
there is no vaccine against HCV, the identification of
infected individuals is mandatory for preventing the
increasing prevalence of the disease [9,20].
Although the WHO states that dentists are at greater risk
of HCV, a number of studies have shown that the preva-
lence of HCV infection in this group is similar (1.2%) [33]
or even lower (0.0%) [34] than that of the general popu-
lation [9]. The possibility of becoming infected by HCV is
most commonly related to age and work experience [35].
Two studies carried out in mid-sized cities throughout
Brazil describe a prevalence of 0.7% [35] and 0.4% [36]
among dentists. However, there are no studies on the
prevalence of HCV among dentists in large urban centres
in Brazil.
Thus, the aim of the present study was to investigate the
seroprevalence and sociodemographic data, health-
related and occupational factors and other correlates of




Belo Horizonte is the capital of the state of Minas Gerais
(Brazil). It is an industrialized city with about 2.4 million
inhabitants and considerable social, economic and cul-
tural disparities. There are 2766 dentists registered at the
Minas Gerais Dental Council and working regularly in
Belo Horizonte [37]. These dentists were first contacted,
enrolled and invited to take part in this study in Novem-
ber 2004 when all dentists registered at the Minas Gerais
Dental Council were required to elect the administrative
board of the council. A day was scheduled at a clinical
analysis laboratory at the Medical School of the Federal
University of Minas Gerais for the dentists who chose to
take part in the study. We also published notes on the
risks of hepatitis C in dental practice and the importance
of undergoing the test in the Dental Council newsletter,
the goal of which was to invite dentists to take part in the
study.
The sample size was calculated to give a 95% CI, a level of
precision of 0.75% [37] and using 3% prevalence of hep-
atitis C [9]. The inclusion criteria were dentists, who lived
and worked in the city of Belo Horizonte and registered at
the Minas Gerais Dental Council. This group consists of a
finite population of 2766 dentists. The minimum sample
size to satisfy the requirements was estimated at 1156
dentists. Taking into account the possibility of losses of
previously enrolled dentists, a correction factor of 1.2 was
adopted, totalizing an expected sample size of 1387 den-
tists. These dentists (n = 1387) scheduled a visit at the
clinical analysis laboratory at the Medical School of the
Federal University of Minas Gerais. In sequence, a total
sample of 1302 dentists (response rate = 93.9%) answered
the questionnaire and had a blood sample collected
between December 2004 and June 2006. All participants
had signed a term of informed consent and data were col-
lected on demographic, behavioural and occupational
exposure aspects.Page 2 of 8
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A self-administered questionnaire consisting of twenty
open-ended and close-ended items was used for the data
collection. The drafting of this questionnaire complied
with all steps proposed by previous studies [38,39]. Once
the purpose of the study and its conceptual basis were
defined, the drafting of the items was carried out by
means of a broad-based review of the literature
[3,7,33,40]. Content validation was performed to deter-
mine the suitability of the theoretical content and func-
tionality of the questionnaire. Item selection, adaptation
and additional inclusions were then performed based on
the opinion of an expert in research and marketing. Sub-
sequently, an opinion was formulated by a commission
made up of professionals from different dental institu-
tions and specialties. The commission members and the
expert were aware of the objectives and methodology of
the study and were asked to express their opinions on the
writing and understanding of the questions. Unanimity in
the approval of the questionnaire was required for valida-
tion. Suggestions for changes were heeded when brought
up repeatedly by different commission members.
Response options were organized vertically. All survey
items were constructed in the same format in order to
avoid placing emphasis on any specific item. Space was
included for participants to answer the question when the
multiple choice form was not possible.
The following variables were taken into account:
1- Personal and behavioural data
Gender; sexual behaviour (unprotected homo/hetero sex
with a casual partner); blood transfusions; knowledge of
the results of hepatitis A and C tests; liver pain; abdominal
pain; previous history of hepatitis in participant or family
member; and the use of illicit injection drug. Since the lat-
ter variable is quite sensitive, this point was addressed in
combination with exposure factors, such as the use of
piercing and tattoos, history of any kind of transplant,
dialysis, colonoscopy and chemotherapy.
2- Professional, behavioural and occupational exposure data
Work experience; workplace; field of work; compliance
with Individual Protective Equipment (IPE); vaccination
for hepatitis B; immunized against hepatitis B; history and
number of needle stick accidents with visible bleeding;
dental assistance for patients with hepatitis; and whether
the dentists' clinical dental chart contains a question on a
history of hepatitis.
As people may go to school at any time of their lives and
the number of years of professional activity could be more
important than age in representing their exposure to risk
factors, the age of the participants was not inquired, but
rather the duration of activity (work experience).
For the purpose of this study, the number of needle stick
accidents was categorized into four groups: none; less
than 5; 5 to 10; or more than 10 accidents. In order to ana-
lyze the influence of work experience, the sample was cat-
egorized into four groups: less than 10 years; 10 to 20
years; 21 to 30 years; and 30 years or more. The workplace
was considered as public, private or both.
Blood collection and laboratory tests
Blood samples were collected by peripheral venipuncture
from all 1302 dentists. After centrifugation, all sera sam-
ples were frozen at -80°C until two hours prior to the test.
The samples were tested for antibodies against hepatitis C
(anti-HCV) using a commercially available enzyme-
linked immunosorbent assay (ELISA) (ABBOTT/
MUREX™, Anti-HCV 3.0, Chicago, IL, USA). The assay was
calibrated to international standards, following the man-
ufacturer's recommendations. Specificity is greater than
99% [41,42] and its sensibility is 97.2% [43].
So, individuals positive for anti-HCV were recalled for fur-
ther evaluation at a later date. A detailed clinical examina-
tion was performed and blood samples were drawn to
repeat the anti-HCV tests, serum ALT estimations, HCV
RNA determinations and ultrasound liver examinations.
The presence of HCV RNA in the anti-HCV-positive sam-
ples was assessed by reverse transcription-polymerase
chain reaction (RT-PCR). RT-PCR is considered gold
standard, with greater sensibility than other quantitative
methods and specificity of 98% to 99% [41,42].
The Human Research Ethics Committee of the Federal
University of Minas Gerais (Brazil) approved the protocol
for this study. All voluntaries signed an informed consent
form, where they were informed about the implications of
the results of the tests. Furthermore, they were informed
by the consent form about the implications of the results
of the tests. Each participant received the results of the
tests and information about their clinical implications.
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS for Windows, version 17.0, SPSS
Inc, Chicago, IL, USA). Bivariate analysis was the initial
analytic strategies (Fisher exact test). Afterwards, we per-
formed multivariate logistic regression. The model adjust-
ment was verified by Hosmer & Lemeshow test.
Seroprevalence of hepatitis C was dependent variable. The
significance level was set at α = 0.05.
Results
A total of 68.4% of the dentists were female. Regarding
specialty or field of work, 40.1% reported being general
dentists and the others were distributed among the differ-
ent specialties recognized by the Brazilian Federal Council
of Dentistry.Page 3 of 8
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determinant factors of hepatitis C among Brazilian den-
tists. The seroprevalence of anti-HCV was 0.9% (95% IC
0.5-1.7%). The factors associated to the prevalence of hep-
atitis C were a history of blood transfusion (p = 0.002)
and having undergone a test for hepatitis C (p = 0.015).
Among the 11 dentists who were positive for HCV, 36.4%
reported a history of blood transfusion and 27.3%
reported having undergone a test of hepatitis C. Among
the 1235 individuals who not positive for HCV, 5.0%
reported a history of blood transfusion. Among the 1137
individuals negative for HCV, 4.8% reported having
undergone the test. None of the other factors studied was
associated with the seroprevalence of hepatitis C (p ≥
0.05).
Considering that two independent variables were associ-
ated to seroprevalence, we performed multivariate logistic
regression. However the model did not converge. Thus,
Fisher exact test was performed to evaluate the association
between these two variables ("Test for hepatitis C" and
"Blood transfusion"). Results of this test (p = 0.523)
showed that there was no association between these vari-
ables and indicated that both were independently associ-
ated to seroprevalence (Table 2).
Discussion
The prevalence of chronic HCV infection in the general
population is not uniform across countries and ranges
from 0.1 to 5%, with an extraordinary high prevalence
reported in Egypt (20-25%) [11]. The transmission of
blood-borne viruses in dental offices is a potential hazard
to patients and dental staff, particularly to oral and maxil-
lofacial surgeons [5]. Thus, the present study focused on
the prevalence of anti-HCV among dentists in the city of
Belo Horizonte, Brazil. The overall seroprevalence of HCV
was 0.9% among a calculated sample of 1302 dentists
tested. This is lower than the 1.42% prevalence of HCV
reported for the general population [23] and 1.7% among
Amazon Amerindian populations [24]. However, the
prevalence of hepatitis C among dentists reported here is
higher than the 0.0095% found in a recent similar study
[43] involving 1056 Swiss dental healthcare workers (834
dentists; 222 dental hygienists and assistants). The preva-
lence is also higher than that identified in mid-size Brazil-
ian cities, such as Sertãozinho [35] and Piracicaba [36]. It
is important to notice that none of these Brazilian studies
had a randomized sample. Despite the sample of the
present study is not a randomized sample, our sample is
the biggest sample among these Brazilian studies. Moreo-
ver, data provided by Minas Gerais Dental Council
showed that the proportion of female dentists was of 62%
among the population of dentists in Belo Horizonte. This
data was very similar to our sample (68% of female den-
tists).
The low prevalence of HCV in dentists described in a pre-
vious report [44] and confirmed here might suggest that
dentists have a lower risk of HCV infection caused by
occupational accidents than expected by the WHO [9].
Professional data, behaviour and occupational exposure
were not associated to the seroprevalence of hepatitis C.
This may be explained by the relatively low infectivity of
HCV found in saliva or by the small volume of blood
inoculation involved in dental accidents [44,45]. The par-
ticipants' responses were self-reported; hence, caution
with generalizations must be considered. Volunteers may
have habits or behaviour different from their self-reported
behaviour, meaning that some level of information bias
could exist.
In our study all dentists with positive results were consid-
ered asymptomatic and only three knew of their condi-
tion as an HCV carrier. These dentists were offered further
medical assistance by hepatologists. Thus, the investiga-
tion gave them the opportunity to become aware of their
status as a HCV carrier. There are several advantages to the
early diagnosis of hepatitis C. Infected individuals must
be made aware of self-care and behaviour that could has-
ten the progression of liver disease, such as alcohol intake.
In addition, early diagnosis allows infected people to
receive appropriate preventive services (e.g., hepatitis A
and B vaccination) and to be referred to a clinic for evalu-
ation and HCV therapy [11,21].
The association found between blood transfusion and
hepatitis C reveals dentists have a predisposing factor to
this disease that is common to the general populations.
The risk of contamination with hepatitis C through a
blood transfusion is currently very low in the world
[46,47]. Prior to 1992, however, no HCV detection test
was carried out on blood donors [19]. In Brazil, tests for
the detection of HCV among blood donors were only
mandatory beginning in 1993.
Although the prevalence of hepatitis C found in this study
was low, the number of reported accidents with needle
sticks was unexpectedly high, suggesting that permanent
vigilance and educational programs addressing hepatitis
C virus infection among dentists are necessary. Although
the probability of infection due to contaminated needle
sticks is lower for HCV than HBV [34], this is an important
issue considering the seroprevalence of hepatitis C in the
Brazilian population [23-32] and the issue of dentists
being exposed often to this type of accident [34].
The present study has some limitations that must be rec-
ognized. Cross-sectional studies are carried out either at a
single point in time or over a short period. Thus, associa-
tions identified in cross-sectional studies should not be
considered a causal relationship. However, there is a lackPage 4 of 8
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Male 3 (25.0) 408 (31.6) 411 (31.6) 0.762
Female 9 (75.0) 882 (68.4) 891 (68.4)
Total 12 (100.0) 1290 (100.0) 1302 (100.0)
Work experience†
Less than 10 years 2 (16.7) 349 (27.6) 351 (27.5) 0.233
10 - 20 years 5 (41.6) 339 (26.7) 344 (26.9)
21 - 30 years 2 (16.7) 420 (33.2) 422 (33.0)
More than 30 years 3 (25.0) 158 (12.5) 161 (12.6)
Total 12 (100.0) 1266 (100.0) 1278 (100.0)
Workplace†
Public 1 (9.1) 276 (23.3) 277 (23.2) 0.301
Private 4 (36.4) 536 (45.3) 540 (45.2)
Both 6 (54.5) 372 (31.4) 378 (31.6)
Total 11 (100.0) 1184 (100.0) 1195 (100.0)
Field of Work†
General dentistry 6 (66.7) 514 (47.6) 520 (47.7) 0.111
Oral Surgery/Periodontology 0 (0.0) 159 (14.7) 159 (14.6)
Operative Dentistry/Endodontics 0 (0.0) 183 (16.9) 183 (16.8)
Paediatric Dentistry/Orthodontis 1 (11.1) 157 (14.5) 158 (14.5)
Oral Public Health 1 (11.1) 44 (4.1) 45 (4.1)
Oral Pathology/Oral Radiology 1 (11.1) 24 (2.2) 25 (2.3)
Total 9 (100.0) 1081 (100.0) 1090 (100.0)
IPE use
Yes 7 (58.3) 842 (65.3) 849 (65.2) 0.762
No 5 (41.7) 448 (34.7) 453 (34.8)
Total 12 (100.0) 1290 (100.0) 1302 (100.0)
Vaccinated for Hepatitis B†
Yes 9 (90.0) 953 (84.8) 962 (84.8) 1.000
No 1 (10.0) 171 (15.2) 172 (15.2)
Total 10 (100.0) 1124 (100.0) 1134 (100.0)
Immunized against Hepatitis B†
Yes 2 (22.2) 191 (19.8) 193 (19.8) 1.000
No 7 (77.8) 774 (80.2) 781 (80.2)
Total 9 (100.0) 965 (100.0) 974 (100.0)
Needle stick accidents†
Yes 12 (100.0) 1091 (85.1) 1103 (85.2) 0.233
No 0 (0.0) 191 (14.9) 191 (14.8)
Total 12 (100.0) 1282 (100.0) 1294 (100.0)
Number of needle stick accidents†
None 0 (0.0) 191 (15.0) 191 (14.8) 0.495
Less than 5 8 (66.6) 651 (51.0) 659 (51.2)
5 - 10 2 (16.7) 264 (20.7) 266 (20.7)
More than 10 2 (16.7) 170 (13.3) 172 (13.3)
Total 12 (100.0) 1276 (100.0) 1288 (100.0)Page 5 of 8
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Yes 2 (20.0) 362 (35.9) 364 (35.7) 0.345
No 8 (80.0) 637 (63.1) 645 (63.3)
Total 10 (100.0) 1009 (100.0) 1019 (100.0)
Dental history question about hepatitis†
Yes 11 (100.0) 1063 (83.3) 1074 (83.4) 0.228
No 0 (0.0) 213 (16.7) 213 (16.6)
Total 11 (100.0) 1276 (100.0) 1287 (100.0)
Unprotected homo/hetero sex†
Yes 3 (25.0) 264 (20.6) 267 (20.7) 0.721
No 9 (75.0) 1015 (79.4) 1024 (79.3)
Total 12 (100.0) 1279 (100.0) 1291 (100.0)
Blood transfusion†
Yes 4 (36.4) 62 (5.0) 66 (5.3) 0.002
No 7 (63.6) 1173 (95.0) 1180 (94.7)
Total 11 (100.0) 1235 (100.0) 1246 (100.0)
Knowledge of hepatitis A test result†
Yes 2 (18.2) 58 (5.3) 60 (5.4) 0.115
No 9 (81.8) 1042 (94.7) 1051 (94.6)
Total 11 (100.0) 1100 (100.0) 1111 (100.0)
Knowledge of hepatitis C test result†
Yes 3 (27.3) 55 (4.8) 58 (5.1) 0.015
No 8 (72.8) 1082 (95.2) 1090 (94.9)
Total 11 (100.0) 1137 (100.0) 1148 (100.0)
Liver pain†
Yes 1 66 (5.5) 67 (5.3) 0.478
No 11 1197 (94.5) 1208 (94.7)
Total 12 (100.0) 1208 (100.0) 1275 (100.0)
Abdominal pain†
Yes 0 98 (7.7) 98 (7.6) 1.000
No 12 1177 (92.3) 1189 (92.4)
Total 12 (100.0) 1275 (100.0) 1287 (100.0)
Previous history of hepatitis†
Yes 2 129 (10.5) 131 (10.6) 0.369
No 10 1094 (89.5) 1104 (89.4)
Total 12 (100.0) 1223 (100.0) 1235 (100.0)
History of hepatitis in family†
Yes 5 291 (29.3) 296 (29.5) 0.171
No 5 702 (70.7) 707 (70.5)
Total 10 (100.0) 993 (100.0) 1003 (100.0)
Combined question†, ††
Yes 1 163 (13.1) 164 (13.0) 1.000
No 11 1082 (86.9) 1093 (87.0)
Total 12 (100.0) 1245 (100.0) 1257 (100.0)
* Fisher's exact test
† For these variables, the sum of the data does not result in 100%, as these questions were not answered by the entire sample.
††: This question included use of illicit injection drugs, piercings and tattoos, blood transfusion, transplant, history of dialysis, colonoscopy or 
chemotherapy.
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Virology Journal 2009, 6:228 http://www.virologyj.com/content/6/1/228of studies that concomitantly assess different variables
associated to hepatitis C among dentists, as we performed
in the present study.
As no vaccine or immunoglobulin HCIg against HCV is
available, it is virtually impossible to prevent HCV infec-
tion after occupational exposure. Thus, every precaution
must be taken to prevent infection, including the screen-
ing and testing of blood and organ donors; the inactiva-
tion of the HCV virus in plasma-derived products, the
permanent vigilance and maintenance of the best preven-
tive practices in healthcare settings, including the need for
continual infection control policies in dentistry and the
proper treatment of contaminated patients [9,21].
Conclusions
The seroprevalence of anti-HCV among dentists was low
and no occupational exposure conditions were associated
to the seroprevalence of hepatitis C.
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